DENVER / May 18, 2023 / Business Wire / Modivcare Inc. (the “Company” or “Modivcare”) (Nasdaq: MODV), a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions focused on improving health outcomes, today announced that the Company and its former Chief Executive Officer, Daniel E. Greenleaf, have recently resolved a disagreement regarding the nature of his departure and the amount of compensation owed to him following his departure from the Company effective August 1, 2022. Modivcare and Mr. Greenleaf are pleased to have the dispute amicably resolved and behind them.
Modivcare’s Board Chairman, Christopher Shackelton, stated, “Modivcare appreciates the leadership Dan provided to the company during a critical time, allowing the company to navigate the challenges posed by COVID. We wish him the best on his next challenge.” Mr. Greenleaf stated, “I continue to believe in Modivcare’s mission, and it was an honor to work with so many others dedicated to that mission.”
About Modivcare
Modivcare Inc. (Nasdaq: MODV) is a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions for public and private payors and their members. Our value-based solutions address the social determinants of health (SDoH), enable greater access to care, reduce costs, and improve outcomes. We are a leading provider of non-emergency medical transportation (NEMT), personal care and remote patient monitoring. To learn more about Modivcare, please visit www.modivcare.com.
Last Trade: | US$0.99 |
Daily Change: | -0.13 -11.61 |
Daily Volume: | 657,279 |
Market Cap: | US$14.080M |
March 06, 2025 October 23, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load